Bristol Myers Squibb has announced plans to invest $40 billion in the United States over the next five years, focusing on expanding its domestic research, development, and manufacturing capabilities.
The investment will be directed toward advancing U.S.-based research and development, building out domestic manufacturing infrastructure, and incorporating emerging technologies such as artificial intelligence and machine learning to accelerate drug discovery and development.
A company spokesperson confirmed the planned spending to Reuters, positioning it as part of a broader industry response to shifting U.S. trade policy.
CEO Christopher Boerner stated that strengthening domestic production will improve oversight of complex pharmaceutical supply chains and align manufacturing more closely with where the company conducts most of its research. Boerner also noted plans to scale up radiopharmaceutical production as part of the initiative.
The announcement comes as President Donald Trump continues to threaten tariffs on pharmaceutical imports. On Monday, Trump signed an executive order aimed at expediting the approval process for domestic pharmaceutical manufacturing facilities, a regulatory shift intended to boost onshore production.
The order directs federal agencies to prioritize U.S.-based plants, improve enforcement on foreign ingredient sourcing, and coordinate permitting through a central contact. Framed as a national security measure, the policy seeks to reduce reliance on imports and ensure the U.S. can produce its own medical supplies in future crises.
Although the pharmaceutical sector has largely been shielded from tariffs in the past due to the potential risks to public health, recent rhetoric suggests that drug imports may soon face new restrictions.
Several major drugmakers have ramped up U.S. investment as a precaution, aiming to reduce reliance on foreign supply chains and mitigate the potential impact of future tariffs.
Bristol Myers Squibb’s focus on radiopharmaceuticals follows its $4.1 billion acquisition of RayzeBio in 2024, a deal that added several investigational cancer therapies to its pipeline. The new investment is expected to help bring those and other therapies closer to commercial production within the U.S. while reinforcing supply chain resilience.
